William Privitera
Psychiatry · Austin, TXNPI 1275746034
Payments from drug & device makers
Across 636 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$893
- Takeda Pharmaceuticals U.S.A., Inc.$839
- Lundbeck LLC$640
- plus $4K from 23 others
What the payments were for
- Food & beverage$11,53799%
- Education$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 157 | $2,227 |
| Otsuka America Pharmaceutical, Inc. | 80 | $1,503 |
| Alkermes, Inc. | 68 | $1,466 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $893 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $839 |
| Lundbeck LLC | 31 | $640 |
| Bausch Health US, LLC | 30 | $604 |
| Vanda Pharmaceuticals Inc. | 31 | $591 |
| Johnson & Johnson | 23 | $520 |
| Axsome Therapeutics, Inc. | 18 | $452 |
| Corium, LLC | 27 | $424 |
| Neurocrine Biosciences, Inc. | 21 | $347 |
| E.r. Squibb & Sons, L.L.C. | 5 | $209 |
| Supernus Pharmaceuticals, Inc. | 13 | $194 |
| Teva Pharmaceuticals USA, Inc. | 7 | $152 |
| Arbor Pharmaceuticals, Inc. | 6 | $89 |
| Idorsia Pharmaceuticals US Inc | 4 | $80 |
| Acadia Pharmaceuticals Inc | 3 | $75 |
| Sunovion Pharmaceuticals Inc. | 5 | $64 |
| Noven Therapeutics, LLC | 3 | $59 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $32 |
| Eisai Inc. | 1 | $24 |
| Noven Pharmaceuticals, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Tris Pharma Inc | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Neos Therapeutics, LP | 1 | $12 |
| TMS Neurohealth Centers Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,609 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AzstarysSerdexmethylphen/Dexmethylphen | 30 | $18,899 |
| Lisdexamfetamine Dimesylate | 56 | $12,310 |
| VyvanseLisdexamfetamine Dimesylate | 23 | $10,702 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 93 | $3,231 |
| Aripiprazole | 32 | $1,964 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 19 | $857 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 16 | $812 |
| Dextroamphetamine Sulfate | 11 | $788 |
| Methylphenidate Hcl | 30 | $772 |
| Bupropion XlBupropion Hcl | 27 | $733 |
| Lamotrigine | 29 | $648 |
| Trazodone Hcl | 43 | $555 |
| Mirtazapine | 15 | $524 |
| Duloxetine Hcl | 14 | $437 |
| Escitalopram Oxalate | 15 | $329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corium, LLCAzstarys | $424 | $18,89930 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $839 | $10,70223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Austin
- David BrownAustin$15.8M
- Divyansu PatelAustin$2.8M
- Donald GarciaAustin$2.8M
- Arvinder Pal WaliaAustin$2.5M
- Charles SweetAustin$520K
- Charles NemeroffAustin$429K
- Scott BartleyDallas$42.7M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.